Andrew P. Han

The company saw strong uptake of its sequencing platforms in the clinical oncology market, a trend that is projected to continue in 2022.

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.

During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.